Enhanced survival, reinnervation, and functional recovery of intrastriatal dopamine grafts co-transplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms.
Dopaminergic (DA) micrografts were co-transplanted with Schwann cells (SC) overexpressing 18 kDa and 21/23 kDa FGF-2 into the caudate-putamen unit (CPu) of unilaterally 6-hydroxydopamine-lesioned rats. We report here that SC engineered to overexpress FGF-2 promoted DA-graft-induced restoration, whether co-transplanted at the same site or grafted at a second more distant site within the CPu. In addition, the 21/23 kDa FGF-2 isoforms resulted in a significantly better reinnervation and survival of dopaminergic micrografts when compared to the 18-kDa FGF-2 isoform. However, this effect was not that distinct on functional recovery due to, for example, ceiling effects. One main finding of this study was the influence of the gene promotor on DA survival, respectively, vector-mediated trophism. Therefore, comparisons in terms of survival between 18 kDa and higher molecular weight (HMW) FGF-2 are complicated in the mixed grafted experiments. Furthermore, the first demonstration of the presence of the 21/23 kDa FGF-2 isoforms in the nigrostriatal system and their potent neurotrophic in vivo activities, as shown in the present study, suggest (I) a physiological role of these proteins for dopaminergic neurons and (II) a restorative potential under normal as well as regenerative processes. However, FGF-2-mediated effects are more pronounced after co-transplantation with SC/DA cells mixed in one suspension at the same implantation side than in the side-by-side approach with a spatially and temporally separated transplantation of SC (day 1) and DA-cells (day 3). These findings indicate the necessity of direct contact between FGF-2 and DA-neurons, further elucidate the neurotrophic role of FGF-2 for DA-neurons and highlight the differential restorative potentials of its respective isoforms. We propose that administration of HMW FGF-2 may be used to improve function in the rat Parkinson's disease model.
Timmer
Marco
M
Department of Neuroanatomy, Center of Anatomy, OE 4140, Hannover Medical School, D-30623 Hannover, Germany.
Müller-Ostermeyer
Frauke
F
Kloth
Verena
V
Winkler
Christian
C
Grothe
Claudia
C
Nikkhah
Guido
G
D000818:Animals; D016380:Brain Tissue Transplantation / Q000379:methods; D002470:Cell Survival / Q000235:genetics; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004298:Dopamine / Q000096:biosynthesis; D015259:Dopamine Agents / Q000494:pharmacology; D005260:Female; D016332:Fetal Tissue Transplantation / Q000379:methods; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis* / Q000235:genetics; D018014:Gene Transfer Techniques; D006085:Graft Survival / Q000235:genetics*; D008636:Mesencephalon / Q000166:cytology / Q000196:embryology; D008970:Molecular Weight; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000378:metabolism / Q000637:transplantation*; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D020033:Protein Isoforms / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function; D012583:Schwann Cells / Q000166:cytology / Q000378:metabolism* / Q000637:transplantation*; D016896:Treatment Outcome
D015259:Dopamine Agents; D020033:Protein Isoforms; D016222:Fibroblast Growth Factor 2; D004298:Dopamine